Resverlogix Corp.
RVXCF
Rank in Stocks
#26570
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Share Price
$0.05548
Last synced: 2026-11-09
Market Cap
$19.50M
Change (1 day)
14.39%
Change (1 year)
-23.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Resverlogix Corp. (RVXCF)
Category
Healthcare
Operating Margin for Resverlogix Corp. (RVXCF)
Operating Margin as of November 2026 TTM: 0.00%
According to Resverlogix Corp.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Resverlogix Corp. from 2002 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | -26,691.77% | -96.61% |
| 2010 | -787,524.33% | 5,577.31% |
| 2009 | -13,871.44% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -5,478.74% | 110.17% |
| 2006 | -2,606.87% | 58.96% |
| 2005 | -1,639.97% | -79.25% |
| 2004 | -7,903.73% | 0.00% |
| 2003 | 0.00% | -100.00% |
| 2002 | -663.84% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Resverlogix Corp.'s operating margin
What was Resverlogix Corp.'s operating margin in 2025?
In 2025, Resverlogix Corp.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Resverlogix Corp.'s operating margin changed since 2020?
From 2020 to 2025, Resverlogix Corp.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Resverlogix Corp.'s operating margin compare with similar companies?
Resverlogix Corp.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.